Timeline At The Top: What Witty Did At GSK
This article was originally published in Scrip
Executive Summary
Sir Andrew Witty has announced his intention to retire as CEO of GlaxoSmithKline PLC in March 2017. Having joined as a graduate trainee in 1985, he became CEO in 2008. Eight years is a long time to head up a big pharma company, and while Sir Andrew's detractors might argue that he has failed to deliver shareholder value, none can argue that it has been for lack of action. Here is a timeline of major events at GSK since the start of his tenure at the top.
You may also be interested in...
Lilly BioMedicines Head Ricks Tasked With Overseeing Growth Phase As Next CEO
Long-time CEO John Lechleiter, who led the company through a challenging period of enormous patent expirations, will step down at year's end.
2Q Preview: GSK, Bayer, Celgene, Amgen, AZ, BMS, Sanofi, Merck, Abbvie
GSK, Bayer, Celgene, Amgen, AstraZeneca, Bristol-Myers Squibb, Sanofi, Merck & Co and AbbVie are among the pharma companies due to report second-quarter results imminently. As the financial reporting season moves into a second week, Scrip takes a look at the key things to watch for.
What’s On CEO Andrew Witty’s To-Do List Before Exiting GSK
The company showed signs of stabilization in the first quarter, as Witty insisted his diversified strategy is beginning to pay off. But a new CEO will have to contend with the potential entry of Advair generics.